ReviewTurkish journal of ophthalmology2025
Ab Interno Goniotomy/Goniectomy Techniques
Review in Turkish journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07418853 (Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries
Who cites it
2 citing papers in PubMed.
- Surgical Success and Predictive Factors in Patients Undergoing Gonioscopy-Assisted Transluminal Trabeculotomy.Turkish journal of ophthalmology · 2025Article
- Sectoral excisional goniotomy with Kahook Dual Blade: nasal versus inferior angle treatment.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimally invasive glaucoma surgeries (MIGS), such as Kahook Dual Blade (KDB), bent ab interno needle goniectomy (BANG), gonioscopy-assisted transluminal trabeculotomy (GATT), OMNI, Trabectome, Streamline, and TrabEx+, have significantly advanced the treatment of glaucoma by improving aqueous humor outflow and reducing intraocular pressure (IOP). These innovative procedures target the trabecular meshwork (TM) and Schlemm’s canal, offering effective alternatives to more invasive filtration surgeries. By enhancing the natural drainage pathways, MIGS can achieve notable reductions in IOP and minimize the need for long-term glaucoma medications. Each device has a distinct mechanism of action. The KDB excises a strip of TM, while BANG uses a bent hypodermic needle for controlled goniectomy. GATT performs a 360-degree trabeculotomy using a microcatheter or Prolene (polypropylene) suture to open Schlemm’s canal. OMNI combines canaloplasty and trabeculotomy in a single procedure. The Trabectome ablates TM tissue with electrical energy, whereas Streamline performs viscodilation to expand outflow channels. TrabEx+ facilitates goniectomy with integrated irrigation and aspiration. Clinical studies have shown these MIGS techniques to be both safe and effective, with fewer complications compared to traditional surgeries like trabeculectomy or tube shunt implantation. MIGS procedures are particularly appealing due to their reduced recovery time and lower risk profile. However, further research is essential to establish their long-term efficacy and durability. Continued advancements and comprehensive long-term studies will ensure that MIGS provide sustainable and reliable benefits for glaucoma patients, optimizing treatment strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.